Galimedix Therapeutics, Inc.

  • Home
  • About
    • Overview
    • Strategy
    • Management Team
    • Board of Directors
  • Products
  • Technology
    • Overview
    • MOA
    • Preclinical Experiments
    • Glaucoma Preclinical Data
    • AMD Preclinical Data
    • Trigger Effect
    • Superior Approach
    • Neurorestoration
  • Clinical Trials
  • References
  • News & Media
    • Press Releases
    • Presentations
    • Posters
    • Events
    • In the News
    • Videos
  • Contact

In the News

News & Media

News & Media

  • Press Releases
  • Presentations
  • Posters
  • Events
  • In the News
  • Videos
Improved sensitivity of microperimetric outcomes for clinical studies in age‑related macular degeneration

Improved sensitivity of microperimetric outcomes for clinical studies in age‑related macular degeneration

Mar 2, 2021

The Aβ aggregation modulator MRZ-99030 prevents and even reverses synaptotoxic effects of Aβ1-42 on LTP even following serial dilution to a 500:1 stoichiometric excess of Aβ1-42, suggesting a beneficial prion-like seeding mechanism

Aug 3, 2020

The Future of Treating Alzheimer’s Disease: Aducanumab & Beyond

Jun 19, 2020

Digging deep in the retina pipeline

Nov 13, 2019
RSS
© 2022 Galimedix Therapeutics, Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap